Prof Del Aguila

Current Status of Islet Cell Replacement and Regeneration Therapy Philippe A. Halban, Michael S. German, Steven E. Kahn, and Gordon C. Weir Department of Genetic Medicine and Development (P.A.H.), University of Geneva, 1211 Geneva 4, Switzerland; Hormone Research Institute (M.S.G.), Diabetes Center, University of California, San Francisco, San Francisco, California 94143-0534; Department of Medicine (S.E.K.), Division of Metabolism, Endocrinology, and Nutrition, Veterans Affairs Puget Sound Health Care System and University of Washington, Seattle, Washington 98195; and Section of Islet Transplantation and Cell Biology (G.C.W.), Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts 02215 Context: cell mass and function are decreased to varying degrees in both type 1 and type 2 diabetes. In the future, islet cell replacement or regeneration therapy may thus offer therapeutic benefit to people with diabetes, but there are major challenges to be overcome. Evidence Acquisi

March 31, 2010 Joint Statement on Radioactive Precautions Following Radioactive Iodine Therapy The American Thyroid Association (ATA), The Endocrine Society (TES), the Society of Nuclear Medicine (SNM), the American Association of Clinical Endocrinologists (AACE) Radioactive iodine (I-131) has been used for decades as an effective treatment for thyroid cancer. Throughout this time, one important aspect of such treatment has been the protection of the public, and more specifically household contacts, from theoretically dangerous exposure to residual radiation remaining in the patient’s body after treatment. The Nuclear Regulatory Commission (NRC), an agency of the Federal government, sets the rules governing this aspect of I-131 treatment and revises them periodically 1 . In 1997, the NRC modified these regulations to allow individualization of the procedure for preventing radiation exposure to the public after a patient is treated with I-131. A goal of this rule change